145 related articles for article (PubMed ID: 23151133)
1. Proteasome inhibition in transplantation-focusing on the experience with bortezomib.
Liang Y; Liu H
Curr Pharm Des; 2013; 19(18):3299-304. PubMed ID: 23151133
[TBL] [Abstract][Full Text] [Related]
2. Proteasome inhibitors as immunosuppressants: biological rationale and clinical experience.
Moran E; Carbone F; Augusti V; Patrone F; Ballestrero A; Nencioni A
Semin Hematol; 2012 Jul; 49(3):270-6. PubMed ID: 22726551
[TBL] [Abstract][Full Text] [Related]
3. Proteasome inhibition for antibody-mediated allograft rejection.
Sadaka B; Alloway RR; Shields AR; Schmidt NM; Woodle ES
Semin Hematol; 2012 Jul; 49(3):263-9. PubMed ID: 22726550
[TBL] [Abstract][Full Text] [Related]
4. Protective immunity and use of bortezomib for antibody-mediated rejection in a pediatric kidney transplant recipient.
Claes DJ; Yin H; Goebel J
Pediatr Transplant; 2014 Jun; 18(4):E100-5. PubMed ID: 24725066
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib.
Sun K; Welniak LA; Panoskaltsis-Mortari A; O'Shaughnessy MJ; Liu H; Barao I; Riordan W; Sitcheran R; Wysocki C; Serody JS; Blazar BR; Sayers TJ; Murphy WJ
Proc Natl Acad Sci U S A; 2004 May; 101(21):8120-5. PubMed ID: 15148407
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib rescue therapy in a patient with recurrent antibody-mediated rejection after lung transplantation.
Baum C; Reichenspurner H; Deuse T
J Heart Lung Transplant; 2013 Dec; 32(12):1270-1. PubMed ID: 24041981
[No Abstract] [Full Text] [Related]
7. Dissecting bortezomib: development, application, adverse effects and future direction.
Cao B; Li J; Mao X
Curr Pharm Des; 2013; 19(18):3190-200. PubMed ID: 23151134
[TBL] [Abstract][Full Text] [Related]
8. Proteasome inhibition with bortezomib: an effective therapy for severe antibody mediated rejection after renal transplantation.
Sureshkumar KK; Hussain SM; Marcus RJ; Ko TY; Khan AS; Tom K; Vivas CA; Parris G; Jasnosz KM; Thai NL
Clin Nephrol; 2012 Mar; 77(3):246-53. PubMed ID: 22377258
[TBL] [Abstract][Full Text] [Related]
9. Proteasome inhibitor treatment of antibody-mediated allograft rejection.
Woodle ES; Alloway RR; Girnita A
Curr Opin Organ Transplant; 2011 Aug; 16(4):434-8. PubMed ID: 21753709
[TBL] [Abstract][Full Text] [Related]
10. Discovery and development of second-generation proteasome inhibitors.
Kirk CJ
Semin Hematol; 2012 Jul; 49(3):207-14. PubMed ID: 22726543
[TBL] [Abstract][Full Text] [Related]
11. Proteasome inhibitors: antitumor effects and beyond.
Nencioni A; Grünebach F; Patrone F; Ballestrero A; Brossart P
Leukemia; 2007 Jan; 21(1):30-6. PubMed ID: 17096016
[TBL] [Abstract][Full Text] [Related]
12. Use of systemic proteasome inhibition as an immune-modulating agent in disease.
Mattingly LH; Gault RA; Murphy WJ
Endocr Metab Immune Disord Drug Targets; 2007 Mar; 7(1):29-34. PubMed ID: 17346202
[TBL] [Abstract][Full Text] [Related]
13. Proteasome inhibitors.
Cvek B
Prog Mol Biol Transl Sci; 2012; 109():161-226. PubMed ID: 22727422
[TBL] [Abstract][Full Text] [Related]
14. Clinical and investigational use of proteasome inhibitors for transplant rejection.
Sadaka B; Alloway RR; Woodle ES
Expert Opin Investig Drugs; 2011 Nov; 20(11):1535-42. PubMed ID: 21916809
[TBL] [Abstract][Full Text] [Related]
15. The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus.
Alexander T; Sarfert R; Klotsche J; Kühl AA; Rubbert-Roth A; Lorenz HM; Rech J; Hoyer BF; Cheng Q; Waka A; Taddeo A; Wiesener M; Schett G; Burmester GR; Radbruch A; Hiepe F; Voll RE
Ann Rheum Dis; 2015 Jul; 74(7):1474-8. PubMed ID: 25710470
[TBL] [Abstract][Full Text] [Related]
16. Management of antibody-mediated rejection in transplantation.
Sadaka B; Alloway RR; Woodle ES
Surg Clin North Am; 2013 Dec; 93(6):1451-66. PubMed ID: 24206861
[TBL] [Abstract][Full Text] [Related]
17. Differential effect of bortezomib on HLA class I and class II antibody.
Philogene MC; Sikorski P; Montgomery RA; Leffell MS; Zachary AA
Transplantation; 2014 Sep; 98(6):660-5. PubMed ID: 24798311
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of chronic graft-vs-host disease with retention of anti-myeloma effects by the proteasome inhibitor bortezomib.
Todisco E; Sarina B; Castagna L; Mazza R; Rahal D; Nozza A; Santoro A
Leuk Lymphoma; 2007 May; 48(5):1015-8. PubMed ID: 17487745
[No Abstract] [Full Text] [Related]
19. The role of proteasome inhibition with bortezomib in the treatment of antibody-mediated rejection after kidney-only or kidney-combined organ transplantation.
Flechner SM; Fatica R; Askar M; Stephany BR; Poggio E; Koo A; Banning S; Chiesa-Vottero A; Srinivas T
Transplantation; 2010 Dec; 90(12):1486-92. PubMed ID: 21042239
[TBL] [Abstract][Full Text] [Related]
20. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection.
Walsh RC; Everly JJ; Brailey P; Rike AH; Arend LJ; Mogilishetty G; Govil A; Roy-Chaudhury P; Alloway RR; Woodle ES
Transplantation; 2010 Feb; 89(3):277-84. PubMed ID: 20145517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
